



Original Article

Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial



Alvar Agusti^{a,*}, José Luis Lopez-Campos^{b,c}, Marc Miravittles^d, Juan Jose Soler-Cataluña^{c,e,f}, Jose Maria Marin^g, Borja G. Cosio^h, Bernardino Alcázar-Navarreteⁱ, Jose Maria Echave-Sustaeta^j, Ciro Casanova^k, German Peces-Barba^l, Juan Pablo de-Torres^m, Alberto Fernandez-Villar^{c,n}, Julio Ancochea^o, Felipe Villar-Alvarez^p, Miguel Roman-Rodriguez^q, Jesus Molina^{r,s}, Juan Luis Garcia-Rivero^t, Cruz Gonzalez^u, Patricia Sobradillo^v, Rosa Faner^w, Carolina Peña^x, Raj Sharma^y, José Luis Izquierdo^z, Bartolome R. Celli^{aa}

^a Cátedra Salud Respiratoria, Universidad Barcelona, Institut Respiratori, Clinic Barcelona, FCRB-IDIBAPS, CIBERES, Spain

^b Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Spain

^c Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

^d Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

^e Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, Valencia, Spain

^f Departamento de Medicina, Universitat de València, Spain

^g Respiratory Service, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain

^h Department of Respiratory Medicine, Hospital Universitario Son Espases-IdISBa, Universidad de las Islas Baleares, CIBERES, Spain

ⁱ Servicio de Neumología, Hospital Universitario Virgen de las Nieves, IBS-Granada, Universidad de Granada, CIBERES, Spain

^j Pulmonary Department, Hospital Universitario Quirónsalud Madrid, Universidad Europea de Madrid, Spain

^k Pulmonary Department – Research Unit, Hospital Universitario Nuestra Señora de La Candelaria, CIBERES, ISCIII, Universidad de La Laguna, Santa Cruz de Tenerife, Spain

^l Pulmonology Department, IIS Fundación Jiménez Díaz, CIBERES, Spain

^m Pulmonary Department, Clínica Universidad de Navarra, IdisNa, Spain

ⁿ Servicio de Neumología, Hospital Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain

^o Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, CIBER Enfermedades Respiratorias, Madrid, Spain

^p Pulmonology Department, IIS Fundación Jiménez Díaz, Universidad Autónoma of Madrid, CIBER Enfermedades Respiratorias, Madrid, Spain

^q Primary Care Health Service Mallorca, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa) Palma, Universidad de las Islas Baleares, Spain

^r Centro de Salud Francia, Fuenlabrada, Madrid, Spain

^s Dirección Asistencial Oeste, Spain

^t Respiratory Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

^u Respiratory Department, Hospital Clínico Universitario, Valencia, Spain

^v Pulmonology Department, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain

^w Biomedicine Department, University of Barcelona, FCRB-IDIBAPS, CIBERES, Barcelona, Spain

^x GSK, Madrid, Spain

^y GSK, London, UK

^z Department of Medicine and Medical Specialties, Universidad de Alcalá, Alcalá de Henares, Madrid, Respiratory Medicine, Hospital Universitario de Guadalajara, Guadalajara, Spain

^{aa} Harvard Medical School, Boston, USA

ARTICLE INFO

Article history:

Received 4 March 2024

Accepted 15 April 2024

Available online 25 April 2024

Keywords:

Chronic bronchitis
Emphysema
Exacerbations
GOLD groups
Tobacco smoking
Inhaled steroids

ABSTRACT

Introduction: Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control (CC), a composite outcome that considers both impact and disease stability in a subgroup of GOLD B patients (here termed GOLD B+ patients) characterized by: (1) remaining symptomatic (CAT ≥ 10) despite regular LABA/LAMA therapy; (2) having suffered one moderate exacerbation in the previous year; and (3) having blood eosinophil counts (BEC) ≥ 150 cells/ μ L.

Methods: The ANTES B+ study is a prospective, multicenter, open label, randomized, pragmatic, controlled trial designed to test this hypothesis. It will randomize 1028 B+ patients to continue with their usual LABA/LAMA combination prescribed by their attending physician or to begin fluticasone furoate (FF) 92 μ g/umeclidinium (UMEC) 55 μ g/vilanterol (VI) 22 μ g in a single inhaler q.d. for 12 months. The primary efficacy outcome will be the level of CC achieved. Secondary outcomes include the clinical important

* Corresponding author.
E-mail address: aagusti@clinic.cat (A. Agusti).

deterioration index (CID), annual rate of exacerbations, and FEV1. Exploratory objectives include the interaction of BEC and smoking status, all-cause mortality and proportion of patients on LABA/LAMA arm that switch therapy arms. Safety analysis include adverse events and incidence of pneumonia.

Results: The first patient was recruited on February 29, 2024; results are expected in the first quarter of 2026.

Conclusions: The ANTES B+ study is the first to: (1) explore the efficacy and safety of triple therapy in a population of B+ COPD patients and (2) use a composite index (CC) as the primary result of a COPD trial.

© 2024 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 document recommends initial treatment with dual long-acting bronchodilator therapy (long-acting β_2 adrenergic (LABA) and long-acting muscarinic antagonist (LAMA)) in patients with chronic obstructive pulmonary disease (COPD) group B, as defined by a COPD Assessment Test (CAT) ≥ 10 and none or one moderate exacerbation (treated with oral corticosteroids and/or antibiotics) in the previous year.¹ Three potential caveats, however, need to be considered here. First, recent research has shown that GOLD B patients with one previous moderate ECOPD have a higher hazard ratio of future exacerbation, all-cause and respiratory hospitalization than those without it.² Second, it is known that patients who remain symptomatic (CAT ≥ 10) despite treatment with LABA/LAMA are at higher risk of worse health outcomes.¹ And third, it is now well recognized that a higher level of circulating eosinophils (Eos) identifies patients at increased risk of future ECOPD, a better preventive response to inhaled corticosteroids (ICS), and reduced risk of ICS-related pneumonia.³ Collectively, these observations call for reconsideration of the potential role of triple therapy (LABA/LAMA/ICS) in some B patients (from now on termed B+ patients) who may be at increased risk of poor clinical control and disease progression if treated with LABA/LAMA only. Specifically, we propose that B+ patients would be characterized by the coexistence of the following three phenotypic traits: (1) remain symptomatic (CAT ≥ 10) despite current treatment with LABA/LAMA; (2) have suffered one moderate ECOPD the previous year; and (3) have a blood eosinophil count (BEC) ≥ 150 cells/ml. We hypothesize that triple therapy will result in better disease control and prevent disease progression than dual bronchodilator treatment in B+ patients.

On the other hand, historically the main outcomes of randomized clinical trials (RCT) in patients with COPD have been either the level of symptoms (using a variety of questionnaires), lung function changes, the annual rate of ECOPD and/or mortality.⁴ However, a recent consensus document for COPD pharmacological RCTs concludes that “... the use of the new tools, particularly combination endpoints, could help better identify the right patients to be treated with the new drugs”.⁵ So far, however, no previous COPD RCT have used a combined endpoint as its primary outcome, at variance with cardiovascular RCTs that frequently use them (e.g., major adverse cardiovascular events – MACE).⁶ There are several combined endpoints that can be potentially used in RCTs in COPD,⁵ including the clinically important deterioration (CID),⁷ early clinically important improvement,⁸ COPDCompEx⁹ and clinical control (CC).^{10–17} As shown in Fig. 1, the latter includes two disease dimensions (impact and stability); a patient is considered “clinically controlled” if both the stability criteria and 3 out of 4 of the impact criteria are met. CC has been validated in several national and international studies that demonstrate that it predicts the risk of future exacerbations and the time to the next exacerbation.^{10–17} But the ANTES B+ study presented below will be the first RCTs to use a composite outcome (CC) to investigate the efficacy of a pharmacological intervention in COPD. This study has been conceived and designed by the Sci-

entific Committee of the ANTES program, a multicenter program sponsored by GSK in Spain that aims at anticipating the diagnosis and treatment of COPD by: (1) improving COPD underdiagnosis; (2) acting earlier in younger patients; (3) early therapeutic optimization; (4) achieving an exacerbation zero goal; and (5) improve survival.^{18,19} Specifically, the ANTES B+ study is a collaborative study between the ANTES academic investigators in Spain and GSK aimed at testing the hypothesis that the use of triple therapy in a single inhaler (fluticasone furoate (FF) 92 μ g/umeclidinium (UMEC) 55 μ g/vilanterol (VI) 22 μ g) improves CC during 1 year follow-up in a larger proportion of B+ patients vs. the currently recommended dual bronchodilator treatment, as prescribed by the attending physician of the patient (LABA/LAMA).¹ Here, we present the main aspects of the study protocol and discuss their novelty and potential relevance.

The ANTES B+ Study

Study Design

The ANTES B+ study is a prospective, multicenter, open label, randomized, pragmatic controlled pilot study in B+ COPD patients (ClinicalTrials.gov NCT06282861). Patients will be characterized at recruitment and then randomized in a 1:1 ratio to continue with their usual LABA/LAMA combination (as prescribed by their attending physician, hence a pragmatic design) or fluticasone furoate (FF) 92 μ g/umeclidinium (UMEC) 55 μ g/vilanterol (VI) 22 μ g in a single inhaler q.d. for 12 months. To minimize the effect of potential imbalance in the number of patients across centers, patients will be stratified *per site*. Likewise, randomization will be stratified *per site* for BEC (between 150 and 300 Eos/mL and more than 300 Eos/mL) to facilitate *post hoc* group comparisons. Then patients will be visited in the participating centers (all in Spain, both in primary and specialized care) at 6 and 12 months and contacted by phone at 3 and 9 months. The first patient was included in the study on February 29, 2024, and results are expected in the first quarter of 2026.

Ethics

The study protocol has been approved by the Ethics Committee of The Balearic Islands (Mallorca, Spain) and the Spanish National Agency for Drugs and Treatments (AEMPS). All patients will provide written informed consent before any study procedures are performed. This trial will be conducted in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, Good Clinical Practice guidelines as well as with all the appropriate Spanish and European regulations for biomedical research.

Objectives

Primary

To determine the efficacy of FF/UMEC/VI in a single inhaler q.d. vs. the LABA/LAMA combination the patient was already receiving

Questionnaire on clinical control in COPD			
Stability	S₁ How have you been since your last visit? ☐ Better ☐ The same ☐ Worse		
	S₂ Have you had any exacerbations in the last 3 months? ☐ No ☐ Yes		
	☐ Stable (Must meet all criteria)		
	☐ Unstable (If any of the criteria are met)		
Impact	I₁ What color has your sputum been in the last few days? ☐ White / clear or no sputum ☐ Dark		
	I₂ How many times have you used the rescue medication in the past week? (Number of occasions rescue medication is required, regardless of the number of inhalations used each time) ☐ < 3 times / week ☐ ≥ 3 times / week		
	I₃ How long (on average) have you walked per day in the last week? ☐ ≥ 30 minutes a day ☐ < 30 minutes a day		
	I₄ What is the current grade of dyspnea (mMRC scale)? I_{4a} FEV₁ ≥ 50% ☐ Dyspnea 0 - 1 I_{4b} FEV₁ < 50% ☐ Dyspnea 0 - 2 I_{4c} FEV₁ ≥ 50% ☐ Dyspnea ≥ 2 I_{4d} FEV₁ < 50% ☐ Dyspnea ≥ 3		
	☐ Low impact (Must meet 3 of the 4 criteria)		
	☐ High impact (If at least 2 criteria are met)		
	☐ Grade 0: No dyspnea, except with strenuous exercise ☐ Grade 1: Dyspnea when hurrying on a level or when walking up a slight hill ☐ Grade 2: Dyspnea makes it impossible for them to keep up with other people of the same age on a level, or forces them to stop or rest when walking on level ground at their own pace ☐ Grade 3: Dyspnea when walking less than 100 meters on level ground ☐ Grade 4: Dyspnea prevents the patient from leaving home or appears with activities such as dressing or undressing		
Control	Stability ☐ + ☐ Low impact		Instability ☐ Or ☐ High impact
	☐ Control (Must meet all criteria)		☐ No control (If any of the criteria are met)

Arch Bronconeumol. 2022;58:T69–T81

Fig. 1. Domains of the clinical control (CC) composite outcome. For further explanations, see text.

Reproduced with permission from Ref. 12.

(as prescribed by their attending physician) in achieving a better CC in COPD B+ patients, a composite outcome that considers both impact and disease stability (Fig. 1), over a year follow-up.

Secondary

To determine the efficacy of FF/UMEC/VI in a single inhaler q.d. vs. the LABA/LAMA combination the patient was already receiving (as prescribed by their attending physician) in COPD B+ patients on: (1) CID (using the CAT questionnaire), another validated composite endpoint⁸ in COPD not used as the primary outcome in any previous COPD RCT; (2) annual rate of exacerbations and FEV1 changes; and (3) the proportion of permanently vs. intermittently vs. never CC status over the study period.

Exploratory

The following exploratory objectives will be analyzed in COPD B+ patients: (1) the primary and secondary endpoints discussed above in patients stratified by BEC (150–300 Eos/mL or >300 Eos/mL) or smoking status (current vs. former); (2) comparison between CC and CID-CAT results; (3) all-cause mortality between the two study arms; and (4) proportion of patients on LABA/LAMA arm that are switched to triple therapy (or vice versa), as per their physician's prescription.

Safety Analyses

The annual incidence of adverse events and severe adverse events will be compared in both groups, including the frequency of pneumonia between the two groups.

Table 1
Trial Population of the B+ Study.

Inclusion criteria	
• Female or male.	
• 40–80 yrs. of age.	
• Current/former smokers ≥10 pack-year.	
• Diagnosis of COPD according to GOLD 2024 (post-BD FEV1/FVC <0.7 in the appropriate clinical context) with FEV1 post-BD 30–70% of the reference value.	
• B+ phenotype.	
◦ CAT ≥ 10 despite being on LABA/LAMA for ≥3 months.	
◦ 1 moderate ECOPD in the previous year (treated with a short course of oral steroids and/or antibiotics).	
◦ ≥ 150 blood Eos/mL (as determined by a single Eos measurement in the previous 12 months available in the medical record of the patient).	
• A signed and dated written informed consent prior to study participation.	
Exclusion criteria	
• GOLD E (≥2 moderate or 1 severe ECOPD in the previous year).	
• ICS treatment (or oral steroid for whatever reason) during the last 8 weeks. ²²	
• ECOPD during the last 8 weeks. ²²	
• Current diagnosis of asthma or documented history of asthma in the medical record of the patient according to the 2023 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.	
• Other concomitant respiratory disease (e.g., bronchiectasis, lung fibrosis, lung neoplasm).	
• Use of domiciliary long-term oxygen therapy or non-invasive ventilation.	
• Alpha-1 antitrypsin deficiency.	
• Unstable or life-threatening cardiac disease, including:	
• Myocardial infarction or unstable angina in the last 6 months.	
• Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months.	
• NYHA class IV heart failure.	
• Starting a Pulmonary Rehabilitation Program within the 4 weeks prior to screening, or planning to do so during the study.	
• Long-term antibiotic therapy (antibiotics are allowed for the short-term treatment of an exacerbation or for short-term treatment of other acute infections during the study).	
• Systemic, oral, parenteral corticosteroids used for COPD and/or other diseases in the 8 weeks before entering in the study (oral/systemic corticosteroids may be used to treat COPD exacerbations during the study).	
• Active neoplasm.	
• Life expectancy <1 yr.	
• Current participation in other RCTs.	
• Non-compliance: subjects at risk of non-compliance, or unable to comply with the study procedures.	
• Any disease, disability, or geographic location that would limit compliance for scheduled visits.	
• Known allergy to FF/UMEC/VI q.d. components (vilanterol, umecclidinium and/or fluticasone furoate) or inability to use the Ellipta® device.	
• Women who are pregnant or lactating or are planning to become pregnant during the study.	

	Inclusion visit	3 month follow-up	6 month follow-up	9 month follow-up	12 month follow-up
Time (Days)	0	90 ± 7	180 ± 15	270 ± 15	365 ± 15
Type of visit					
Informed consent	X				
Inclusion / exclusion criteria	X				
Demographics	X		X		X
Comorbidities and concomitant medication	X	X	X	X	X
Symptoms (MCR, CAT)	X	X	X	X	X
Clinical control (CC)	X	X	X	X	X
Vital signs	X		X		X
Forced spirometry	X		X		X
Treatment Compliance (TAI)	X	X	X	X	X
Adverse events	X	X	X	X	X
Blood tests	X		X		X

Fig. 2. Trial assessment and procedures throughout the study. For further explanations, see text.

Study Population

The inclusion and exclusion criteria of the study population are listed in Table 1. Patients will be recruited from Hospitals and Primary Care centers around Spain.

Assessment and Procedures

Fig. 2 summarizes all trial assessment and procedures throughout the study. Patient compliance with the trial intervention will be monitored in each of the follow-up visits through the Test of Adherence to Inhalers (TAI) questionnaire.²⁰ Concomitant therapy for potential comorbidities will be allowed as per the attending physician and recorded appropriately. Short-acting bronchodila-

tors as rescue therapy will be allowed (and recorded as measure of “clinical control” (Fig. 1)). The Barcelona Clinical Coordinating Center (<https://bcccbarcelona.com/en/>) of the Private Foundation Mon Clínic Barcelona will provide support for the study as an academic Contract Research Organization.

Statistical Analysis

Sample Size Determination

There is no published data available in the study population of COPD B+ patients that allows a precise estimation of the sample size for the ANTES B+ trial. Accordingly, we used data published in other, generally more severe, COPD populations^{21–23} to estimate it. According to these previous reports, we hypothesized that: (1) 30%

of B+ patients treated with LABA/LAMA will be CC at all clinical visits during the study duration (permanent CC) and (2) that FF/UMEC/VI q.d. will improve the number of CC patients by 9% (up to 39%). Based on these calculations, the expected odds ratio (OR) to be detected is 1.49. Thus, for a bilateral test, with α -risk of 0.05, and a β -risk of 0.2 (80% power), assuming that a 15% of patients can be lost during follow-up, we estimated that the study needs to recruit a total of 1028 patients, and that 514 patients need to be randomized to each arm of the study (LABA/LAMA or FF/UMEC/VI q.d.).

Data Analysis

Standard descriptive statistics (n , range, %, mean $\pm$ standard deviation, median [interquartile range – IQR]) and unpaired T -test for continuous normally distributed parameters, chi-square test to compare qualitative variables or the Wilcoxon rank-sum test for continuous parameters not normally distributed will be used to compare the main characteristics of both groups at recruitment, in order to ensure that the two arms are comparable at baseline. The analysis of the primary and secondary objectives will be based on a two-sided univariate analysis and several multivariate adjusted models. Endpoints involving time to first event will be assessed by using Kaplan–Meier models, compared by log-rank tests, with univariate and multivariate Cox regression models (covariates including but not limited to age, sex, FEV1, smoking). For exploratory objectives, correlations between dimensions and variables that forms each tool Correlations index (Pearson's correlation coefficient or Cohen's kappa coefficient) will be used. The combination of Kaplan–Meier models, compared by log-rank tests, with univariate and multivariate logistic regression models, Cox regression models will be used to assess all-cause mortality. Data analysis will be conducted using R and SPSS.

Discussion

The working hypothesis of the ANTES B+ study is that triple therapy improves a novel composite health outcome (CC) in a particular subgroup of GOLD B patients (B+ patients). No previous study has investigated this hypothesis before, so the ANTES B+ study is exploring new territory. However, some recent previous studies in different patient populations provide the rationale to test it. First, the E-max study by Maltais et al. showed that a LABA–LAMA combination was more effective in terms of symptom improvement (transitional dyspnea index) than any of the two bronchodilators alone²²; in fact, this forms the basis for the GOLD recommendation of a LABA–LAMA combination as starting treatment in B patients.¹ Second, in a short study (12 weeks), Han et al. failed to show that dual bronchodilator treatment decrease respiratory symptoms in symptomatic, tobacco-exposed persons with preserved lung function as assessed by spirometry, although it improved significantly after treatment.²⁴ Third, two large RCTs (IMPACT²¹ and ETHOS²³) showed that, in more severe patients, triple therapy reduces all-cause mortality after one year follow-up; indeed, this is the main reason why GOLD considers the use of triple therapy as initial treatment in GOLD E patients with >300 Eos/ μ L.¹ And, finally, it is now well accepted that the level of circulating eosinophils identifies a group of patients at risk of exacerbations who may respond well to treatment with ICS.³ Because B+ patients have never been studied in isolation, we do not know how Eos levels can inform treatment decisions (dual vs. triple therapy) in B+ patients, but the results of the ANTES B+ study will provide relevant information in this setting.

Another important aspect to note, is that the ANTES B+ study will be the first RCT to use a *composite* outcome (CC) as the primary endpoint in COPD. CC has been validated in several national and international studies that demonstrate that it predicts the risk of future exacerbations and the time to the next exacerbation,^{10–17}

but never before as a measure of the efficacy of a therapeutic intervention. This is perfectly in line with the recently revisited ATS/ERS recommendations on outcomes for COPD pharmacologic trials.⁵

It is also of note that the ANTES B+ study takes a pragmatic approach (the control group will continue to be treated with their LABA/LAMA combination, as prescribed before entering the study by their attending physician), yet robust (1 year-long follow-up using a novel primary composite outcome) to answer a key clinical question in a study population at risk of poor CC. The final strategic goal of the study would be to inform guidelines and to be relevant to prescribing physicians.

The design of the ANTES B+ study is aligned with the strategic goals of the ANTES program, in particular those of early therapeutic optimization, zero exacerbations and, hopefully, improved survival.^{18,19} So far, recommendations for pharmacologic treatment of COPD lagged behind the disease: more symptoms, more treatment; more exacerbations, more treatment.¹ If the ANTES B+ study is positive, this paradigm will have to be revisited to optimize their pharmacological treatment earlier in the course of the disease in B+ patients.

Funding

The ANTES B+ study is a collaborative study between the academic members of the ANTES program and GSK (study number #221775).

Authors' Contributions

AA wrote the first draft of the paper. All authors read it and contributed comments to it. The final manuscript was approved by all authors.

Competing Interests

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Agusti A: declares research support, lecture fees and participation in advisory board in AstraZeneca, Chiesi, GSK, Gebro, Menarini, MSD, Sanofi-Regeneron and/or Zambon. He does not have shares or interest in any company, neither does any member of his family. He has not received or had any relationship with tobacco money.

Lopez-Campos JL has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer, Chiesi, CSL Behring, Faes, Gebro, Grifols, GSK, Menarini, Zambon.

Miravittles M: declares speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Glenmark Pharmaceuticals, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, BEAM Therapeutics, Chiesi, GlaxoSmithKline, CSL Behring, Ferrer, Inhbrx, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi/Regeneron, Zambon, Zentiva and Grifols and research grants from Grifols.

Soler-Cataluña JJ declares grant research from GlaxoSmithKline, speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Menarini, and consulting fees from Bial, Chiesi, and GlaxoSmithKline.

Marin JM declares to have received unrestricted grants from AstraZeneca and GSK and participation in advisory boards for GSK, and Sanofi-Regeneron.

Cosio BG declares grants from Chiesi and GSK; personal fees for advisory board activities from Chiesi, GSK, Novartis, Sanofi, Teva,

and AstraZeneca; and payment for lectures/speaking engagements from Chiesi, Novartis, GSK, Menarini, AstraZeneca, and Sanofi outside the submitted work.

Alcázar-Navarrete B reports grants and personal fees from GSK, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Chiesi, non-financial support from Laboratorios Menarini, grants, personal fees and non-financial support from AstraZeneca, personal fees from Gilead, personal fees and non-financial support from MSD, personal fees from Laboratorios BIAL, personal fees from Zambon, outside the submitted work.

Echave-Sustaeta JM has received speaker or consulting fees from GlaxoSmithKline in the last 3 years.

Casanova C has received speaker or consulting fees from AstraZeneca, GlaxoSmithKline, Menarini, Novartis, and research grants from GlaxoSmithKline, Menarini and AstraZeneca in the last 3 years.

Peces-Barba G declares grants from GSK, Chiesi and Menarini.

De-Torres JP declare lecture fees and participation in advisory boards for GSK, AstraZeneca, Sanofi-Regeneron.

Fernandez-Villar A declares research support, lecture fees and participation in advisory board in AstraZeneca, Chiesi, Grifols and GSK.

Ancochea J declares lecture fees and collaboration or participation in advisory boards for Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Linde Healthcare, Menarini, Mundipharma, Novartis, Roche, Rovi, Sandoz and Teva.

Villar F has attended or participated in activities organized or financed by the pharmaceutical companies Almirall, AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Esteve, Ferrer, Menarini, Novartis, Mundipharma, Orion, Pfizer, Teva and Zambon.

Roman-Rodríguez M declares grants from AZ; personal fees for advisory board activities from GSK and AstraZeneca; and payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Faes, Gebro, GlaxoSmithKline, Menarini, Pfizer, and Sanofi outside the submitted work.

Molina J declares lecture fees and participation in advisory board in AstraZeneca, Chiesi, GSK, and Menarini.

García-Rivero JL reports speaker fees from Gebro Pharma, GSK, AstraZeneca, Chiesi, Menarini and Sanofi; consulting fees from GSK, AstraZeneca, ALK, and Sanofi.

Gonzalez C declares research support, lecture fees and participation in advisory board in AstraZeneca, CLS Behring, Grifols, BIAL, Zambon and GSK.

Sobradillo P has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer, Chiesi, CSL Behring, Faes, Gebro, Grifols, GSK.

Faner R declares research support, lecture fees or participation in advisory boards for AstraZeneca, Chiesi, GSK, Menarini, Sanofi-Regeneron and/or Zambon.

Peña C is a full-time GSK employee.

Sharma R is a full-time GSK employee.

Celli B reports having received compensation for Advisory Boards and consultation fees from: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Pulmonx, Sanofi-Aventis, CHIESI, Menarini and Gala Therapeutics. He does not have shares or interest in any company, neither does any member of his family. He has not received or had any relationship with tobacco money.

Acknowledgments

Authors thank the Barcelona Clinical Coordinating Center of the Private Foundation Mon Clinic in Barcelona (Spain) (<https://bccbarcelona.com/en>), and particularly Lada Murcia (PhD), for their help and outstanding support to develop the study protocol, the eCRF

to be used in the study and all the administrative and logistic issues involved in a large, multicenter RCT like the ANTES B+ study. Authors would also like to acknowledge and thank Almudena Blanco (GSK) for her energy, enthusiasm and support in the ANTES program.

References

- Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. *Arch Bronconeumol*. 2023;59:232–48.
- Vanfleteren L, Lindberg A, Zhou C, Nyberg F, Stridsman C. Exacerbation risk and mortality in global initiative for chronic obstructive lung disease group A and B patients with and without exacerbation history. *Am J Respir Crit Care Med*. 2023;208:163–75.
- Singh D, Agustí A, Martínez FJ, Papi A, Pavord ID, Wedzicha JA, et al. Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. *Am J Respir Crit Care Med*. 2022;206:17–24.
- Cazzola M, MacNee W, Martínez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J*. 2008;31:416–69.
- Cazzola M, Rogliani P, Barnes PJ, Blasi F, Celli B, Hanania NA, et al. An update on outcomes for COPD pharmacological trials: a COPD investigators report – reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. *Am J Respir Crit Care Med*. 2023;208:374–94.
- Rosenblatt M. The large pharmaceutical company perspective. *N Engl J Med*. 2017;376:52–60.
- Singh D, Criner GJ, Naya I, Jones PW, Tombs L, Lipson DA, et al. Measuring disease activity in COPD: is clinically important deterioration the answer? *Respir Res*. 2020;21:134.
- Kostikas K, Mackay AJ, Vogelmeier CF, Frent SM, Gupta P, Banerji D, et al. Early clinically important improvement (ECII) and exacerbation outcomes in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1831–8.
- Vogelmeier CF, Fuhlbrigge A, Jauhiainen A, Scheepers L, Bengtsson T, Peterson S, et al. COPDCompEx: a novel composite endpoint for COPD exacerbations to enable faster clinical development. *Respir Med*. 2020;173:106175.
- Soler-Cataluña JJ, Alcázar-Navarrete B, Miravittles M. The concept of control of COPD in clinical practice. *Int J Chron Obstruct Pulmon Dis*. 2014;9:1397–405.
- Soler-Cataluña JJ, Alcázar-Navarrete B, Miravittles M. The concept of control in COPD: a new proposal for optimising therapy. *Eur Respir J*. 2014;44:1072–5.
- Soler-Cataluña JJ, Marzo M, Catalan P, Miralles C, Alcázar B, Miravittles M. Validation of clinical control in COPD as a new tool for optimizing treatment. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3719–31.
- Soler-Cataluña JJ, Alcázar B, Marzo M, Perez J, Miravittles M. Evaluation of changes in control status in COPD: an opportunity for early intervention. *Chest*. 2020;157:1138–46.
- Miravittles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan JHY, et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. *Respirology*. 2020;25:1136–43.
- Calle Rubio M, Rodríguez Hermosa JL, de Torres JP, Marin JM, Martínez-González C, Fuster A, et al. COPD clinical control: predictors and long-term follow-up of the CHAIN cohort. *Respir Res*. 2021;22:36.
- Soler-Cataluña JJ, Almagro P, Huerta A, González-Segura D, Cosío BG, CLAVE Study Investigators. Clinical control criteria to determine disease control in patients with severe COPD: the CLAVE study. *Int J Chron Obstruct Pulmon Dis*. 2021;16:137–46.
- Soler-Cataluña JJ, Huerta A, Almagro P, González-Segura D, Cosío BG, Investigators CS. Lack of clinical control in COPD patients depending on the target and the therapeutic option. *Int J Chron Obstruct Pulmon Dis*. 2023;18:1367–76.
- Agustí A, Alcázar B, Cosío B, Echave J, Faner R, Izquierdo J, et al. Time for a change: anticipating the diagnosis and treatment of chronic obstructive pulmonary disease. *Eur Respir J*. 2020;56:2002104.
- Agustí A, Alcázar B, Ancochea J, Casanova C, Celli B, Cosío B, et al. ANTES: un año después en la EPOC. *Arch Bronconeumol*. 2022;58:291–4.
- Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, de Llano LP, et al. Validation of the 'Test of the Adherence to Inhalers' (TAI) for asthma and COPD patients. *J Aerosol Med Pulm Drug Deliv*. 2016;29:142–52.
- Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. *N Engl J Med*. 2018;378:1671–80.
- Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res*. 2019;20:238.
- Rabe KF, Martínez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med*. 2020;383:35–48.
- Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, et al. Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function. *N Engl J Med*. 2022;387:1173–84.